Literature DB >> 8558143

MRI dynamics of brain and spinal cord in progressive multiple sclerosis.

D Kidd1, J W Thorpe, B E Kendall, G J Barker, D H Miller, W I McDonald, A J Thompson.   

Abstract

OBJECTIVE: To assess the usefulness of serial cord MRI in patients with progressive multiple sclerosis.
METHODS: Monthly MRI of the brain and spinal cord with and without gadolinium enhancement was carried out in 19 patients with progressive multiple sclerosis (10 primary progressive, nine secondary progressive) over the course of one year.
RESULTS: During this period there were 132 active lesions in the brain and only six in the cord. One hundred and twelve (85%) active brain lesions occurred in the secondary progressive group; three new cord lesions occurred in each group. In the secondary progressive group MRI activity was high in patients who had superimposed relapses, whereas in those who progressed without relapse and in the primary progressive group it was low. Cross sectional areas of the cord decreased at the C5 level in both groups, implying progressive atrophy of fibre tracts. There was no relation between either brain or cord MRI activity and change in disability over the study period.
CONCLUSIONS: Although the detection of new lesions by frequent cord imaging using current technology has little role in the monitoring of disease activity in progressive multiple sclerosis, the serial measurement of cord cross sectional area may be important. There is also evidence to suggest that the mechanism underlying irreversible disability in patients with progressive multiple sclerosis may be different in patients who continue to relapse than in those who do not.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8558143      PMCID: PMC486183          DOI: 10.1136/jnnp.60.1.15

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

Review 1.  The pathological evolution of multiple sclerosis.

Authors:  W I McDonald; D H Miller; D Barnes
Journal:  Neuropathol Appl Neurobiol       Date:  1992-08       Impact factor: 8.090

2.  A comparison of the pathology of primary and secondary progressive multiple sclerosis.

Authors:  T Revesz; D Kidd; A J Thompson; R O Barnard; W I McDonald
Journal:  Brain       Date:  1994-08       Impact factor: 13.501

Review 3.  Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.

Authors:  W I McDonald; D H Miller; A J Thompson
Journal:  Ann Neurol       Date:  1994-07       Impact factor: 10.422

4.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

5.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

Authors:  D W Paty; D K Li
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

6.  Spinal cord MRI using multi-array coils and fast spin echo. I. Technical aspects and findings in healthy adults.

Authors:  J W Thorpe; D Kidd; B E Kendall; P S Tofts; G J Barker; A J Thompson; D G MacManus; W I McDonald; D H Miller
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

7.  Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis.

Authors:  D Kidd; J W Thorpe; A J Thompson; B E Kendall; I F Moseley; D G MacManus; W I McDonald; D H Miller
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

  9 in total
  33 in total

1.  Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis.

Authors:  D B McGavern; P D Murray; C Rivera-Quiñones; J D Schmelzer; P A Low; M Rodriguez
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

Review 2.  Neurological rehabilitation: from mechanisms to management.

Authors:  A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

Review 3.  Prognostic factors for multiple sclerosis: the importance of natural history studies.

Authors:  George C Ebers
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

Review 4.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 5.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

Review 6.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

7.  Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.

Authors:  N Tubridy; H J Ader; F Barkhof; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

8.  Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis.

Authors:  D J Mahad; S J L Howell; M N Woodroofe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Authors:  Y Zoukos; T N Thomaides; D Kidd; M L Cuzner; A Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-02       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.